APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

TNF Inhibitors for the Treatment of Plaque Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Outlook and Growth Opportunities 2026

Report ID 174041650427 December 2025206 pages

Choose your research edition.

Industry ResearchTNF Inhibitors for the Treatment of Plaque Psoriasis Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global TNF Inhibitors for the Treatment of Plaque Psoriasis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the TNF Inhibitors for the Treatment of Plaque Psoriasis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the TNF Inhibitors for the Treatment of Plaque Psoriasis market include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of TNF Inhibitors for the Treatment of Plaque Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the TNF Inhibitors for the Treatment of Plaque Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Company

Chia Tai Tianqing Pharmaceutical

Innovent Biologics

Sino Cell Technologies

Samsung Bioepis

Hangzhou Bozhirui Biopharmaceuticals

Hisun Pharmaceuticals

Bio-Thera Solutions

YL Biologics

UCB

Teva

Sandoz

Pfizer

Janssen Biotech

Coherus BioSciences

Celltrion

Boehringer Ingelheim Pharmaceuticals

Biocon Biologics

Amgen

AbbVie

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type

Adalimumab

Certolizumab pegol

Etanercept

Infliximab

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global TNF Inhibitors for the Treatment of Plaque Psoriasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions TNF Inhibitors for the Treatment of Plaque Psoriasis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify TNF Inhibitors for the Treatment of Plaque Psoriasis significant trends, drivers, influence factors in global and regions.

6. To analyze TNF Inhibitors for the Treatment of Plaque Psoriasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the TNF Inhibitors for the Treatment of Plaque Psoriasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global TNF Inhibitors for the Treatment of Plaque Psoriasis industry.

Chapter 3: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of TNF Inhibitors for the Treatment of Plaque Psoriasis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends Table 2. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers Table 3. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges Table 4. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints Table 5. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Company (2021-2026) Table 7. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Company (K Units) & (2021-2026) Table 8. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Company (2021-2026) Table 9. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price (US$/Unit) of Company (2021-2026) Table 10. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Ranking, (2024-2026) & (USD Million) Table 11. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Company Manufacturing Base & Headquarters Table 12. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company, Product Type & Application Table 13. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adalimumab Table 18. Significant Companies of Certolizumab pegol Table 19. Significant Companies of Etanercept Table 20. Significant Companies of Infliximab Table 21. Significant Companies of Other Table 22. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2021-2026) & (K Units) Table 24. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2027-2032) & (K Units) Table 25. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Type (2021-2026) Table 26. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Type (2027-2032) Table 27. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type (2021-2026) Table 31. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital and Clinic Table 33. Significant Companies of Retail Pharmacies Table 34. Significant Companies of Other Table 35. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2021-2026) & (K Units) Table 37. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2027-2032) & (K Units) Table 38. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Application (2021-2026) Table 39. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Application (2027-2032) Table 40. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application (2021-2026) Table 44. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application (2027-2032) Table 45. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2026) & (K Units) Table 47. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2021-2026) Table 48. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2027-2032) & (K Units) Table 49. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2027-2032) Table 50. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Region (2021-2026) Table 53. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Region (2027-2032) Table 55. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 60. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2026) Table 61. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 62. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2027-2032) Table 63. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Market Share by Country (2021-2026) Table 65. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Market Share by Country (2027-2032) Table 67. Chia Tai Tianqing Pharmaceutical Company Information Table 68. Chia Tai Tianqing Pharmaceutical Business Overview Table 69. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 71. Chia Tai Tianqing Pharmaceutical Recent Development Table 72. Innovent Biologics Company Information Table 73. Innovent Biologics Business Overview Table 74. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 76. Innovent Biologics Recent Development Table 77. Sino Cell Technologies Company Information Table 78. Sino Cell Technologies Business Overview Table 79. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 81. Sino Cell Technologies Recent Development Table 82. Samsung Bioepis Company Information Table 83. Samsung Bioepis Business Overview Table 84. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 86. Samsung Bioepis Recent Development Table 87. Hangzhou Bozhirui Biopharmaceuticals Company Information Table 88. Hangzhou Bozhirui Biopharmaceuticals Business Overview Table 89. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 91. Hangzhou Bozhirui Biopharmaceuticals Recent Development Table 92. Hisun Pharmaceuticals Company Information Table 93. Hisun Pharmaceuticals Business Overview Table 94. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 96. Hisun Pharmaceuticals Recent Development Table 97. Bio-Thera Solutions Company Information Table 98. Bio-Thera Solutions Business Overview Table 99. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 101. Bio-Thera Solutions Recent Development Table 102. YL Biologics Company Information Table 103. YL Biologics Business Overview Table 104. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 106. YL Biologics Recent Development Table 107. UCB Company Information Table 108. UCB Business Overview Table 109. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 111. UCB Recent Development Table 112. Teva Company Information Table 113. Teva Business Overview Table 114. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 116. Teva Recent Development Table 117. Sandoz Company Information Table 118. Sandoz Business Overview Table 119. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 121. Sandoz Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 126. Pfizer Recent Development Table 127. Janssen Biotech Company Information Table 128. Janssen Biotech Business Overview Table 129. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 131. Janssen Biotech Recent Development Table 132. Coherus BioSciences Company Information Table 133. Coherus BioSciences Business Overview Table 134. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 136. Coherus BioSciences Recent Development Table 137. Celltrion Company Information Table 138. Celltrion Business Overview Table 139. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 141. Celltrion Recent Development Table 142. Boehringer Ingelheim Pharmaceuticals Company Information Table 143. Boehringer Ingelheim Pharmaceuticals Business Overview Table 144. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 146. Boehringer Ingelheim Pharmaceuticals Recent Development Table 147. Biocon Biologics Company Information Table 148. Biocon Biologics Business Overview Table 149. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 151. Biocon Biologics Recent Development Table 152. Amgen Company Information Table 153. Amgen Business Overview Table 154. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 156. Amgen Recent Development Table 157. AbbVie Company Information Table 158. AbbVie Business Overview Table 159. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 161. AbbVie Recent Development Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors List Table 165. TNF Inhibitors for the Treatment of Plaque Psoriasis Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. TNF Inhibitors for the Treatment of Plaque Psoriasis Product Image Figure 2. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 4. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adalimumab Image Figure 10. Certolizumab pegol Image Figure 11. Etanercept Image Figure 12. Infliximab Image Figure 13. Other Image Figure 14. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Type (2021-2032) Figure 17. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type (2021-2032) Figure 20. Hospital and Clinic Image Figure 21. Retail Pharmacies Image Figure 22. Other Image Figure 23. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Application (2021-2032) Figure 26. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application (2021-2032) Figure 29. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 34. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 36. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 40. South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Figure 128. Manufacturing Cost Structure Figure 129. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Adalimumab
  • Certolizumab pegol
  • Etanercept
  • Infliximab
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Innovent Biologics
  • Sino Cell Technologies
  • Samsung Bioepis
  • Hangzhou Bozhirui Biopharmaceuticals
  • Hisun Pharmaceuticals
  • Bio-Thera Solutions
  • YL Biologics
  • UCB
  • Teva
  • Sandoz
  • Pfizer
  • Janssen Biotech
  • Coherus BioSciences
  • Celltrion
  • Boehringer Ingelheim Pharmaceuticals
  • Biocon Biologics
  • Amgen
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032)
  4. 1.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume (2021-2032)
  5. 1.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 TNF Inhibitors for the Treatment of Plaque Psoriasis Market Dynamics
  1. 2.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends
  2. 2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers
  3. 2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges
  4. 2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints
3 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Company
  1. 3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Revenue Ranking in 2025
  2. 3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company (2021-2026)
  3. 3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Company (2021-2026)
  4. 3.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price by Company (2021-2026)
  5. 3.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Ranking (2024-2026)
  6. 3.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Manufacturing Base and Headquarters
  7. 3.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Product Type and Application
  8. 3.8 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 TNF Inhibitors for the Treatment of Plaque Psoriasis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Type
  1. 4.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Type Introduction
  2. 4.1.1 Adalimumab
  3. 4.1.2 Certolizumab pegol
  4. 4.1.3 Etanercept
  5. 4.1.4 Infliximab
  6. 4.1.5 Other
  7. 4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type
  8. 4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Type (2021-2032)
  10. 4.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Type (2021-2032)
  11. 4.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type
  12. 4.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Type (2021-2032)
  14. 4.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type (2021-2032)
5 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Application
  1. 5.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application
  6. 5.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume by Application (2021-2032)
  8. 5.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Volume Share by Application (2021-2032)
  9. 5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application
  10. 5.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Application (2021-2032)
  12. 5.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application (2021-2032)
6 TNF Inhibitors for the Treatment of Plaque Psoriasis Regional Sales and Value Analysis
  1. 6.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021-2026
  4. 6.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2027-2032)
  5. 6.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region (2021-2032)
  7. 6.4.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region: 2021-2026
  8. 6.4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Region (2027-2032)
  9. 6.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032)
  12. 6.6.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032)
  15. 6.7.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032)
  21. 6.9.2 South America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Country, 2025 VS 2032
7 TNF Inhibitors for the Treatment of Plaque Psoriasis Country-level Sales and Value Analysis
  1. 7.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  4. 7.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026)
  5. 7.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032)
  6. 7.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2021-2032)
  7. 7.4.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2021-2026)
  8. 7.4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Innovent Biologics
  8. 8.2.1 Innovent Biologics Company Information
  9. 8.2.2 Innovent Biologics Business Overview
  10. 8.2.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  12. 8.2.5 Innovent Biologics Recent Developments
  13. 8.3 Sino Cell Technologies
  14. 8.3.1 Sino Cell Technologies Company Information
  15. 8.3.2 Sino Cell Technologies Business Overview
  16. 8.3.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  18. 8.3.5 Sino Cell Technologies Recent Developments
  19. 8.4 Samsung Bioepis
  20. 8.4.1 Samsung Bioepis Company Information
  21. 8.4.2 Samsung Bioepis Business Overview
  22. 8.4.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  24. 8.4.5 Samsung Bioepis Recent Developments
  25. 8.5 Hangzhou Bozhirui Biopharmaceuticals
  26. 8.5.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
  27. 8.5.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
  28. 8.5.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  30. 8.5.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
  31. 8.6 Hisun Pharmaceuticals
  32. 8.6.1 Hisun Pharmaceuticals Company Information
  33. 8.6.2 Hisun Pharmaceuticals Business Overview
  34. 8.6.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  36. 8.6.5 Hisun Pharmaceuticals Recent Developments
  37. 8.7 Bio-Thera Solutions
  38. 8.7.1 Bio-Thera Solutions Company Information
  39. 8.7.2 Bio-Thera Solutions Business Overview
  40. 8.7.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  42. 8.7.5 Bio-Thera Solutions Recent Developments
  43. 8.8 YL Biologics
  44. 8.8.1 YL Biologics Company Information
  45. 8.8.2 YL Biologics Business Overview
  46. 8.8.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  48. 8.8.5 YL Biologics Recent Developments
  49. 8.9 UCB
  50. 8.9.1 UCB Company Information
  51. 8.9.2 UCB Business Overview
  52. 8.9.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  54. 8.9.5 UCB Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  60. 8.10.5 Teva Recent Developments
  61. 8.11 Sandoz
  62. 8.11.1 Sandoz Company Information
  63. 8.11.2 Sandoz Business Overview
  64. 8.11.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  66. 8.11.5 Sandoz Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Janssen Biotech
  74. 8.13.1 Janssen Biotech Company Information
  75. 8.13.2 Janssen Biotech Business Overview
  76. 8.13.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  78. 8.13.5 Janssen Biotech Recent Developments
  79. 8.14 Coherus BioSciences
  80. 8.14.1 Coherus BioSciences Company Information
  81. 8.14.2 Coherus BioSciences Business Overview
  82. 8.14.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  84. 8.14.5 Coherus BioSciences Recent Developments
  85. 8.15 Celltrion
  86. 8.15.1 Celltrion Company Information
  87. 8.15.2 Celltrion Business Overview
  88. 8.15.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  90. 8.15.5 Celltrion Recent Developments
  91. 8.16 Boehringer Ingelheim Pharmaceuticals
  92. 8.16.1 Boehringer Ingelheim Pharmaceuticals Company Information
  93. 8.16.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  94. 8.16.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  96. 8.16.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  97. 8.17 Biocon Biologics
  98. 8.17.1 Biocon Biologics Company Information
  99. 8.17.2 Biocon Biologics Business Overview
  100. 8.17.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  102. 8.17.5 Biocon Biologics Recent Developments
  103. 8.18 Amgen
  104. 8.18.1 Amgen Company Information
  105. 8.18.2 Amgen Business Overview
  106. 8.18.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  108. 8.18.5 Amgen Recent Developments
  109. 8.19 AbbVie
  110. 8.19.1 AbbVie Company Information
  111. 8.19.2 AbbVie Business Overview
  112. 8.19.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  114. 8.19.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Analysis
  2. 9.1.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Mode & Process
  6. 9.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
  9. 9.2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst